State Action
CCAGW Urges Florida Legislature to Oppose HB 1547 and SB 262
HB 1547 and SB 262 would harm consumers and small businesses.
CCAGW Urges Rhode Island House Innovation, Internet, & Technology Committee to Oppose H 6236
H 6236 will fail to achieve its objective of protecting consumer privacy.
CCAGW Urges Florida Senate Health Policy Committee to Oppose SB 1550
SB 1550 will damage the private sector healthcare market and government healthcare plans.
CCAGW Urges Minnesota Senate State and Local Governments and Veterans Committee to Oppose SF 168
SF 168 would impose price controls on prescription drugs through the establishment of the Prescription Drug Affordability Review Board.
CCAGW Urges Oregon House Behavioral Health and Health Care Committee to Oppose HB 3090
HB 3090 will reduce the use of tobacco harm reduction products, increase the purchase of tobacco products on an unregulated black market, and fail to reduce smoking.
CCAGW Urges North Carolina House Committee on Health to Oppose HB 246
HB 246 would impose onerous regulations on pharmacy benefit managers.
CCAGW Urges Minnesota Senate Judiciary and Public Safety Committee to Oppose SF 168
SF 168 would impose price controls on prescription drugs through the establishment of the Prescription Drug Affordability Review Board.
CCAGW Urges Illinois House Cybersecurity, Data Analytics, & IT Committee to Oppose HB 3385
HB 3385 will fail to achieve its objective of protecting consumer privacy.
CCAGW Urges Alaska House Labor and Commerce Committee to Support HB 35
HB 35 would repeal Alaska's outdated certificate-of-need laws.
CCAGW Urges Oregon Senate Judiciary Committee to Oppose SB 619
SB 619 will fail to achieve its objective of protecting consumer privacy.
CCAGW Urges Minnesota House Health Finance and Policy Committee to Oppose HF 17
HF 17 would impose price controls on prescription drugs through the establishment of the Prescription Drug Affordability Review Board.
CCAGW Urges Minnesota Senate Health and Human Services Committee to Oppose SF 2123
SF 2123 will reduce the use of tobacco harm reduction products (THR), increase the purchase of tobacco products on an unregulated black market, and fail to reduce smoking.
